Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder

EXPERT OPINION ON EMERGING DRUGS · Published 2024-04-29 · DOI 10.1080/14728214.2024.2345645

Authors being retrieved — see the publisher record. https://doi.org/10.1080/14728214.2024.2345645

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2024

Related articles

Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder · EXPERT OPINION ON EMERGING DRUGS · 2024 · Same journal
Emerging drugs for the treatment of irritability associated with autism spectrum disorder · EXPERT OPINION ON EMERGING DRUGS · 2024 · Same journal
At the forefront of gene-based therapies in Dravet syndrome · EXPERT OPINION ON EMERGING DRUGS · 2026 · Same journal
Emerging treatments for sarcoma: from 2024 onward · EXPERT OPINION ON EMERGING DRUGS · 2025 · Same journal
Emerging biological treatments for asthma · EXPERT OPINION ON EMERGING DRUGS · 2025 · Same journal
Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials · EXPERT OPINION ON EMERGING DRUGS · 2023 · Same journal
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond · EXPERT OPINION ON EMERGING DRUGS · 2023 · Same journal
Potential use of psilocybin drugs in the treatment of depression · EXPERT OPINION ON EMERGING DRUGS · 2023 · Same journal
How will tovorafenib change our treatment of pediatric low-grade glioma? · EXPERT OPINION ON EMERGING DRUGS · 2024 · Same journal
Emerging small molecules for ulcerative colitis: clinical advancements and trial insights · EXPERT OPINION ON EMERGING DRUGS · 2026 · Same journal